Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma

Show full item record



Permalink

http://hdl.handle.net/10138/231165

Citation

Ali , A S , Gronberg , M , Federspiel , B , Scoazec , J-Y , Hjortland , G O , Gronbaek , H , Ladekarl , M , Langer , S W , Welin , S , Vestermark , L W , Arola , J , Osterlund , P , Knigge , U , Sorbye , H , Grimelius , L & Janson , E T 2017 , ' Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma ' , PLoS One , vol. 12 , no. 11 , 0187667 . https://doi.org/10.1371/journal.pone.0187667

Title: Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma
Author: Ali, Abir Salwa; Gronberg, Malin; Federspiel, Birgitte; Scoazec, Jean-Yves; Hjortland, Geir Olav; Gronbaek, Henning; Ladekarl, Morten; Langer, Seppo W.; Welin, Staffan; Vestermark, Lene Weber; Arola, Johanna; Osterlund, Pia; Knigge, Ulrich; Sorbye, Halfdan; Grimelius, Lars; Janson, Eva Tiensuu
Contributor: University of Helsinki, HUSLAB
University of Helsinki, Clinicum
Date: 2017-11-07
Language: eng
Number of pages: 15
Belongs to series: PLoS One
ISSN: 1932-6203
URI: http://hdl.handle.net/10138/231165
Abstract: Background Gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs) are aggressive, rapidly proliferating tumors. Therapeutic response to current chemotherapy regimens is usually short lasting. The aim of this study was to examine the expression and potential clinical importance of immunoreactive p53 protein in GEP-NEC. Materials and methods Tumor tissues from 124 GEP-NEC patients with locally advanced or metastatic disease treated with platinum-based chemotherapy were collected from Nordic centers and clinical data were obtained from the Nordic NEC register. Tumor proliferation rate and differentiation were re-evaluated. All specimens were immunostained for p53 protein using a commercially available monoclonal antibody. Kaplan-Meier curves and cox regression analyses were used to assess progression-free survival (PFS) and overall survival (OS). Results All tumor tissues were immunoreactive for either one or both neuroendocrine biomarkers (chromogranin A and synaptophysin) and Ki67 index was >20% in all cases. p53 immunoreactivity was only shown in 39% of the cases and was not found to be a prognostic marker for the whole cohort. However, p53 immunoreactivity was correlated with shorter PFS in patients with colorectal tumors (HR = 2.1, p = 0.03) in a univariate analysis as well as to poorer PFS (HR = 2.6, p = 0.03) and OS (HR = 3.4, p = 0.02) in patients with colorectal tumors with distant metastases, a correlation which remained significant in the multivariate analyses. Conclusion In this cohort of GEP-NEC patients, p53 expression could not be correlated with clinical outcome. However, in patients with colorectal NECs, p53 expression was correlated with shorter PFS and OS. Further studies are needed to establish the role of immunoreactive p53 as a prognostic marker for GEP-NEC patients.
Subject: CONSENSUS GUIDELINES
ENDOCRINE TUMORS
CANCER
PROGRESSION
MUTATIONS
NEOPLASMS
DIAGNOSIS
PANCREAS
TRACT
NEC
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
journal.pone.0187667.pdf 20.62Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record